Taysha Gene Therapies (TSHA) Non Operating Income (2020 - 2026)

Taysha Gene Therapies has reported Non Operating Income for 7 years, with the latest figure at $1.1 million in Q1 2026.

• Quarterly Non Operating Income rose 1096.3% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (up 50.62% YoY) and the FY2025 annual result came in at $1.5 million, down 30.45% from the prior year.
• Non Operating Income climbed to $1.1 million in Q1 2026 per TSHA's latest filing, from $449000.0 in the prior quarter.
• Over five years, Non Operating Income peaked at $64.0 million in Q4 2023 and troughed at -$100.8 million in Q3 2023.
• A 5-year average of -$2.1 million and a median of $199000.0 in 2022 frame the typical range for Non Operating Income.
• The widest YoY moves for Non Operating Income: up 32054.27% in 2023, down 9324.02% in 2023.
• Over 5 years, Non Operating Income stood at $199000.0 in 2022, then soared by 32054.27% to $64.0 million in 2023, then slumped by 98.21% to $1.1 million in 2024, then sank by 60.85% to $449000.0 in 2025, then jumped by 139.64% to $1.1 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered $1.1 million, $449000.0, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.